Autres langues Kronos Bio, Inc.

Actions

KRON

US50107A1043

Temps réel estimé Cboe BZX Autres places de cotation 16:33:27 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,56 ^USD	+8,33 %		+24,80 %	+24,80 %

23/05	Kronos Bio, Inc. présentera une mise à jour clinique sur l'étude de phase 1/2 du KB-0742 lors de la réunion annuelle de l'American Society of Clinical Oncology (ASCO) en 2024	CI
21/05	Kronos Bio, Inc. annonce des changements au sein de sa direction	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05
Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology Annual Meeting	23/05
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events	22/05
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer	21/05
Kronos Bio, Inc. Announces Executive Changes	21/05
Kronos Bio, Inc. Announces Chief Financial Officer Changes	21/05
Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	09/05
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Kronos Bio Reports First-Quarter 2024 Financial Results	09/05
Kronos Bio Reports First-Quarter 2024 Financial Results	09/05
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	21/03
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results	21/03
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway	07/03
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study	07/03
Kronos Bio Plans to Reduction in Force	07/03
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting	05/03
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kronos Bio, Inc.

Actions

KRON

US50107A1043

Autres langues

Filtres